Clinical and Experimental Neuroimmunology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Concentration ‐dependent effects of pro‐inflammatory cytokines on barrier function and tight junction protein expression in brain microvascular endothelial cells and the hypothermic and hyperthermic effects on tight junction protein expression
ConclusionsThe hypothermic suppression of TNF- α and IL-17 release may contribute to the maintenance of BBB function by ameliorating the decrease of TJP(s). In contrast, hyperthermia may decrease barrier function through a decrease in JAM-B expression. However, the contribution of changes in the JAM-B expression to the barrier function of BMVEC s remains to be clarified. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - September 17, 2022 Category: Neurology Authors: Tomohiro Matsui, Yuji Mochiduki, Yusuke Yoshida, Takenori Nitta Tags: ORIGINAL ARTICLE Source Type: research

Mogad Presenting as Recurrent Adem. Case Report of the Youngest Mexican Patient in the Literature
ConclusionsInformation regarding the clinical presentation and evolution among different population could help to a better understanding of the presentation of this entity. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - September 3, 2022 Category: Neurology Authors: Christian Garc ía‐Estrada, Enrique Gómez‐Figueroa, Juan Pablo Morelos‐Cisneros, Alondra Deras‐Martinez Tags: CASE REPORT Source Type: research

Issue Information
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 30, 2022 Category: Neurology Tags: ISSUE INFORMATION Source Type: research

Antimonoclonal antibody treatment for multiple sclerosis and neuromyelitis optica spectrum disorder: An update
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 30, 2022 Category: Neurology Authors: Yuko Shimizu Tags: EDITORIAL Source Type: research

Monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder
AbstractMultiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive monoclonal antibody treatment than ever before. Currently, five monoclonal antibodies for MS or NMOSD are ava...
Source: Clinical and Experimental Neuroimmunology - August 30, 2022 Category: Neurology Authors: Chiyoko Nohara Tags: INVITED REVIEW Source Type: research

The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders
AbstractThe launch of highly efficacious monoclonal antibody (mAb) drugs has profoundly changed the therapeutic strategy for multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD). However, the newly developed mAb drugs, especially those used in treating NMOSD, are quite expensive, resulting in a significant medical and economic burden. Early use of these drugs is expected to reduce the frequency of relapse and the accumulation of disability, preserve the quality of life of patients, and improve their life expectancy. In selecting therapeutic drugs, it is necessary not only to consider the efficacy and safe...
Source: Clinical and Experimental Neuroimmunology - August 30, 2022 Category: Neurology Authors: Takashi Ohashi Tags: INVITED REVIEW Source Type: research

Monoclonal antibody treatment for multiple sclerosis and neuromyelitis optica spectrum disorder: An update
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 30, 2022 Category: Neurology Authors: Yuko Shimizu Tags: EDITORIAL Source Type: research

MOG ‐antibody‐associated disorder with hypothalamic lesions associated with hypersomnia and decrease of orexin in CSF: A case report
ConclusionsThe orexin level in CSF was useful to monitor hypothalamic dysfunction in a patient with MOGAD. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 29, 2022 Category: Neurology Authors: Kanako Menjo, Shinji Ashida, Shohei Murata, Eijirou Tanaka, Chihiro Fujii, Masami Tanaka, Keiko Tanaka, Takashi Kanbayashi, Toshiki Mizuno Tags: CASE REPORT Source Type: research

Anti ‐monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder
AbstractMultiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Anti-monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive anti-monoclonal antibody treatment than ever before. Currently, five anti-monoclonal antibodies for MS o...
Source: Clinical and Experimental Neuroimmunology - August 23, 2022 Category: Neurology Authors: Chiyoko Nohara Tags: INVITED REVIEW Source Type: research

Balo's Concentric Sclerosis or Multiple Sclerosis? A Demyelinating Disease in a 36 ‐year‐old Female
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 4, 2022 Category: Neurology Authors: Jingya Wei, Sa Wang, Juan Kang Tags: CASE IMAGE Source Type: research

Development of infections among patients with myasthenia gravis undergoing immunotherapy
ConclusionAge at onset of MG was a significant contributor to the development of infection. Generalized late-onset MG is the most susceptible to infection and should be carefully monitored during immunotherapy. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - August 4, 2022 Category: Neurology Authors: Shingo Konno, Takafumi Uchi, Jun Isonishi, Mari Matsushima, Hideo Kihara, Hideki Sugimoto, Toshiki Fujioka Tags: ORIGINAL ARTICLE Source Type: research

Disease perception impacts quality of life and fatigue in relapsing –remitting multiple sclerosis patients
ConclusionsOur study showed no association between disease duration and disease perception. Patients with less disease knowledge reported more problems in self-care and higher fatigue scores. Patients with the worst disease expectations were more anxious and reported a worse health status. More attention should be paid to perceived health status in MS patients. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - July 28, 2022 Category: Neurology Authors: Ana Rita Silva, Helena Felgueiras, Ana Isabel Gon çalves, Andreia Fernandes, Bruna Meira, Diana Melância, José Rosa, Maria Teresa Silvério, Ana Macedo Tags: ORIGINAL ARTICLE Source Type: research

Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder
This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - July 26, 2022 Category: Neurology Authors: Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno Tags: INVITED REVIEW Source Type: research

Anti ‐monoclonal antibody treatment during pregnancy and lactation in women with MS or Neuromyelitis optica spectrum disorder
AbstractMultiple sclerosis (MS) and Neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients have poor prognostic factors are treated with highly effective disease modifying drug (DMD) from the beginning. Anti monoclonal antibodies for MS or NMOSD are basically highly effective DMDs. Therefore, young women with MS or NMOSD will have more opportunities to receive anti monoclonal antibody treatment than ever before. Currently five anti monoclonal antibodies for MS or NMOSD are availab...
Source: Clinical and Experimental Neuroimmunology - July 22, 2022 Category: Neurology Authors: Chiyoko Nohara Tags: INVITED REVIEW Source Type: research

The impact of anti ‐monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders
AbstractThe launch of highly efficacious anti-monoclonal antibody (mAb) drugs has profoundly changed the therapeutic strategy for multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD). However, the newly developed anti-mAb drugs, especially those used in treating NMOSD, are quite expensive, resulting in a significant medical and economic burden. Early use of these drugs is expected to reduce the frequency of relapse and the accumulation of disability, preserve the quality of life of patients, and improve their life expectancy. In selecting therapeutic drugs, it is necessary not only to consider the efficac...
Source: Clinical and Experimental Neuroimmunology - July 19, 2022 Category: Neurology Authors: Takashi Ohashi Tags: INVITED REVIEW Source Type: research